Mesoblast Limited (NASDAQ:MESO - Get Free Report) shares gapped up before the market opened on Thursday . The stock had previously closed at $19.80, but opened at $20.81. Mesoblast shares last traded at $21.12, with a volume of 159,945 shares.
Analyst Ratings Changes
A number of research analysts have weighed in on MESO shares. Piper Sandler lifted their target price on Mesoblast from $11.00 to $15.00 and gave the company an "overweight" rating in a report on Thursday, December 19th. Maxim Group raised shares of Mesoblast from a "hold" rating to a "buy" rating and set a $12.00 target price on the stock in a report on Tuesday, September 24th. Jefferies Financial Group downgraded shares of Mesoblast from a "buy" rating to a "hold" rating in a report on Monday, December 23rd. Finally, StockNews.com cut shares of Mesoblast from a "hold" rating to a "sell" rating in a report on Wednesday, September 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $13.50.
View Our Latest Report on Mesoblast
Mesoblast Trading Up 4.1 %
The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18. The business's 50 day moving average is $12.12 and its two-hundred day moving average is $9.00.
Institutional Trading of Mesoblast
A number of hedge funds have recently made changes to their positions in MESO. Marshall Wace LLP purchased a new stake in Mesoblast during the second quarter valued at about $562,000. Signaturefd LLC raised its holdings in shares of Mesoblast by 128.7% during the 3rd quarter. Signaturefd LLC now owns 5,506 shares of the company's stock valued at $45,000 after buying an additional 3,099 shares in the last quarter. Rathbones Group PLC purchased a new position in shares of Mesoblast during the 2nd quarter valued at about $95,000. Creative Planning bought a new stake in Mesoblast in the 3rd quarter worth approximately $147,000. Finally, Perkins Coie Trust Co boosted its stake in Mesoblast by 15.0% in the third quarter. Perkins Coie Trust Co now owns 11,500 shares of the company's stock worth $94,000 after buying an additional 1,500 shares in the last quarter. 1.43% of the stock is owned by institutional investors.
Mesoblast Company Profile
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Featured Stories
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
